In last trading session, Beam Therapeutics Inc. (NASDAQ:BEAM) saw 1.19 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $48.15 trading at -$3.47 or -6.72% at ring of the bell on the day assigns it a market valuation of $3.65B. That closing price of BEAM’s stock is at a discount of -107.81% from its 52-week high price of $100.06 and is indicating a premium of 42.33% from its 52-week low price of $27.77. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.19 million shares which gives us an average trading volume of 1.25 million if we extend that period to 3-months.
For Beam Therapeutics Inc. (BEAM), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.08 in the current quarter.
Beam Therapeutics Inc. (NASDAQ:BEAM) trade information
Upright in the red during last session for losing -6.72%, in the last five days BEAM remained trading in the red while hitting it’s week-highest on Friday, 09/16/22 when the stock touched $48.15 price level, adding 18.2% to its value on the day. Beam Therapeutics Inc.’s shares saw a change of -39.58% in year-to-date performance and have moved -20.40% in past 5-day. Beam Therapeutics Inc. (NASDAQ:BEAM) showed a performance of -11.23% in past 30-days. Number of shares sold short was 13.24 million shares which calculate 8.75 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $93.08 to the stock, which implies a rise of 48.27% to its current value. Analysts have been projecting $60.00 as a low price target for the stock while placing it at a high target of $145.00. It follows that stock’s current price would drop -201.14% in reaching the projected high whereas dropping to the targeted low would mean a loss of -24.61% for stock’s current value.
Beam Therapeutics Inc. (BEAM) estimates and forecasts
Statistics highlight that Beam Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -15.20% of value to its shares in past 6 months, showing an annual growth rate of 21.65% while that of industry is 1.80. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 12.20% in the current quarter and calculating -171.40% decrease in the next quarter. This year revenue growth is estimated to fall -30.40% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $8.39 million for the same. And 9 analysts are in estimates of company making revenue of $6.15 million in the next quarter that will end on Sep 2022.
In 2022, company’s earnings growth rate is likely to be around -37.70% while estimates for its earnings growth in next 5 years are of 4.10%.
Beam Therapeutics Inc. is more likely to be releasing its next quarterly report between March 14 and March 18 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Beam Therapeutics Inc. (NASDAQ:BEAM)’s Major holders
Insiders are in possession of 1.99% of company’s total shares while institution are holding 82.46 percent of that, with stock having share float percentage of 84.14%. Investors also watch the number of corporate investors in a company very closely, which is 82.46% institutions for Beam Therapeutics Inc. that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at BEAM for having 8.79 million shares of worth $340.34 million. And as of Jun 29, 2022, it was holding 12.51% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 5.42 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 7.71% of outstanding shares, having a total worth of $310.29 million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 6.64 million shares of worth $257.19 million or 9.46% of the total outstanding shares. The later fund manager was in possession of 2.16 million shares on Jun 29, 2022, making its stake of worth around $83.79 million in the company or a holder of 3.08% of company’s stock.